Shionogi – GARDP, Cefiderocol License Agreement Post author:GHIAA Admin Post published:July 8, 2022 Post category: Continue ReadingShionogi – GARDP, Cefiderocol License Agreement
Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement Post author:GHIAA Admin Post published:June 8, 2022 Post category: Continue ReadingEntasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement Post author:GHIAA Admin Post published:March 4, 2022 Post category: Continue ReadingBiological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement Post author:GHIAA Admin Post published:February 2, 2022 Post category: Continue ReadingGavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
CEPI – Dynavax, COVID-19 Material Reservation Agreement Post author:GHIAA Admin Post published:January 31, 2022 Post category: Continue ReadingCEPI – Dynavax, COVID-19 Material Reservation Agreement
University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement Post author:GHIAA Admin Post published:January 11, 2022 Post category: Continue ReadingUniversity of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement Post author:GHIAA Admin Post published:January 3, 2022 Post category: Continue ReadingOcugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement Post author:GHIAA Admin Post published:December 13, 2021 Post category: Continue ReadingCureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
BMS – MPP Sublicense & Tech Transfer Agreement Post author:GHIAA Admin Post published:November 30, 2021 Post category: Continue ReadingBMS – MPP Sublicense & Tech Transfer Agreement